Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Solid Biosciences Inc. - Common Stock (NQ:SLDB)

6.960 -0.040 (-0.57%)
Delayed Quote Updated: 12:42 PM EST, Nov 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Solid Biosciences Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an... 
Via MarketMinute
News headline image
Xpeng, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Fed Trims Rates by 0.25%: A New Era of Dovish Policy and Portfolio Rebalancing
The Federal Reserve has announced a 0.25% reduction in its benchmark interest rate, marking a significant shift towards a more accommodative monetary policy. This move, while seemingly modest, carries... 
Via MarketMinute
Topics Bonds Credit Cards Economy
News headline image
Federal Reserve Poised for September Rate Cut Amidst High Market Expectations and Powell's Jackson Hole Address
Investor sentiment is overwhelmingly pointing towards a significant shift in the Federal Reserve's monetary policy, with a near-certainty of a 25-basis-point interest rate cut anticipated at its... 
Via MarketMinute
Topics Bonds Credit Cards Economy
News headline image
Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside ↗
Per two Wall Street analysts, one of 2025's biggest losers could be set up for a stunning recovery. They see over 175% upside in Sarepta Therapeutics. 
Via MarketBeat
Topics Death
News headline image
Solid Biosciences Stock Pops On US, Canada Nod For Gene Therapy Trials: Retail Buzz Spikes ↗
The company plans to begin a Phase 1b trial of SGT-501 later this year, targeting CPVT, a rare and potentially fatal arrhythmia in children and young adults with no current FDA-approved therapies. 
Via Stocktwits
News headline image
Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand ↗
Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenue prospects. 
Via Benzinga
News headline image
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
After a second patient passed away, Sarepta Therapeutics crashed. Solid Biosciences rose over 10% in response. Wall Street sees big upside in both names. 
Via MarketBeat
Topics Earnings
News headline image
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation ↗
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns. 
Via Benzinga
News headline image
Can Solid Biosciences Challenge Sarepta in the DMD Market?
Solid Biosciences' Duchenne muscular dystrophy (DMD) drug could provide superior outcomes compared to an already approved medication projected to make billions. 
Via MarketBeat
News headline image
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week ↗
Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments. 
Via Stocktwits
News headline image
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
Solid Biosciences just saw a 32% move to the upside after its trial results impressed. What's next for this firm that analysts still see massive potential in? 
Via MarketBeat
News headline image
Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move? ↗
Early-stage data from the company's gene therapy candidate SGT-003 for Duchenne muscular dystrophy (DMD) showed encouraging results. 
Via Stocktwits
News headline image
Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data ↗
Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data. 
Via Benzinga
News headline image
Stocks Quiet As S&P 500 Nears All-Time High ↗
All three major indexes are fresh off weekly wins. 
Via Talk Markets
Topics Stocks Stocks / Equities
News headline image
Tuesday's session: gap up and gap down stocks ↗
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
Wondering what's happening in today's pre-market session? ↗
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why BP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development ↗
Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting key 2025 milestones. 
Via Benzinga
News headline image
Why Cal-Maine Foods Shares Are Trading Higher By 4%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst ↗
Wedbush initiates Solid Biosciences with an Outperform rating, citing the potential of SGT-003 for Duchenne muscular dystrophy and a robust cash runway. 
Via Benzinga
News headline image
iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
SLDB Stock Earnings: Solid Biosciences Beats EPS for Q2 2024 ↗
SLDB stock results show that Solid Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
This Planet Fitness Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗
 
Via Benzinga
News headline image
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.